according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

SECTION 1. IDENTIFICATION

Product name : Cefuroxime Formulation

Other means of identification : Spectrazol Milking Cow (A005270)

Coopers Cepravin LC Lactating Cow Intramammary Antibiotic

(47941)

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc Address : 126 E. Lincoln Avenue

Rahway, New Jersey U.S.A. 07065

Telephone : 908-740-4000 Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)

Respiratory sensitization : Category 1

Specific target organ toxicity : Category 2

- repeated exposure

. .

GHS label elements

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H334 May cause allergy or asthma symptoms or breathing diffi-

culties if inhaled.

H373 May cause damage to organs through prolonged or re-

peated exposure.

Precautionary Statements : Prevention:

P260 Do not breathe mist or vapors.

P285 In case of inadequate ventilation wear respiratory protec-

tion.

Response:

P304 + P341 IF INHALED: If breathing is difficult, remove per-

son to fresh air and keep comfortable for breathing.

P342 + P311 If experiencing respiratory symptoms: Call a doc-

tor.

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

Disposal:

P501 Dispose of contents and container to an approved waste

disposal plant.

Other hazards

None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical nameCAS-No.Concentration (% w/w)Cefuroxime55268-75-28.33

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical

advice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

If not breathing, give artificial respiration. If breathing is difficult, give oxygen.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention if symptoms occur.

Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and

delayed

May cause allergy or asthma symptoms or breathing difficul-

ties if inhaled.

May cause damage to organs through prolonged or repeated

exposure.

Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reac-

tive airways dysfunction syndrome).

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

Unsuitable extinguishing

media

: None known.

Specific hazards during fire

fighting

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Nitrogen oxides (NOx)

Sulfur oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for fire-fighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protec: :

tive equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid rele

Avoid release to the environment.

Prevent further leakage or spillage if safe to do so.

Prevent spreading over a wide area (e.g., by containment or

oil barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Soak up with inert absorbent material.

For large spills, provide diking or other appropriate

containment to keep material from spreading. If diked material

can be pumped, store recovered material in appropriate

container.

Clean up remaining materials from spill with suitable

absorbent.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items

employed in the cleanup of releases. You will need to

determine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE

CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation Advice on safe handling Use only with adequate ventilation. Do not breathe mist or vapors.

Do not swallow.

Avoid contact with eyes.

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

Avoid prolonged or repeated contact with skin.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure

assessment

Keep container tightly closed.

Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease,

should consult their physician regarding working with

respiratory irritants or sensitizers.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage : Keep in properly labeled containers.

Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cefuroxime	55268-75-2	TWA	100 μg/m3 (OEB 2)	Internal
	Further information: RSEN			

Engineering measures : Use appropriate engineering controls and manufacturing

technologies to control airborne concentrations (e.g., drip-

less quick connections).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Laboratory operations do not require special containment.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to

maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are

unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided

by air purifying respirators against exposure to any

hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other

circumstance where air purifying respirators may not provide

adequate protection.

Hand protection

Material : Chemical-resistant gloves

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection

Hygiene measures

Work uniform or laboratory coat.

If exposure to chemical is likely during typical use, provide

eye flushing systems and safety showers close to the

working place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : liquid

Color : white

off-white

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapor pressure : No data available

Relative vapor density : No data available

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : Not applicable

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reac- : Can react with strong oxidizing agents.

tions

Conditions to avoid : None known. Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

products

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation Skin contact Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Components:

Cefuroxime:

Acute oral toxicity : LD50 (Rat): > 10,000 mg/kg

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

LD50 (Mouse): > 10,000 mg/kg

Acute toxicity (other routes of :

administration)

LD50 (Rat): > 4,000 mg/kg Application Route: Intravenous

LD50 (Mouse): > 10,000 mg/kg Application Route: Intravenous

LD50 (Rabbit): > 1,500 mg/kg Application Route: Intravenous

LD50 (Dog): > 1,500 mg/kg Application Route: Intravenous

Skin corrosion/irritation

Not classified based on available information.

Serious eye damage/eye irritation

Not classified based on available information.

Respiratory or skin sensitization

Skin sensitization

Not classified based on available information.

Respiratory sensitization

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Components:

Cefuroxime:

Result : Sensitizer

Germ cell mutagenicity

Not classified based on available information.

Components:

Cefuroxime:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Chromosomal aberration

Result: positive

Test Type: In vitro mammalian cell gene mutation test

Test system: mouse lymphoma cells

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

Species: Mouse Result: negative

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

Carcinogenicity

Not classified based on available information.

IARC No ingredient of this product present at levels greater than or equal to 0.1% is

identified as probable, possible or confirmed human carcinogen by IARC.

OSHANo component of this product present at levels greater than or equal to 0.1% is

on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is

identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:

Cefuroxime:

Effects on fertility : Test Type: Fertility

Species: Mouse

Application Route: Oral

Fertility: NOAEL: 6,400 mg/kg body weight

Symptoms: No adverse effects.

Test Type: Fertility Species: Rabbit Application Route: Oral

Fertility: NOAEL: 400 mg/kg body weight

Symptoms: No adverse effects.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs through prolonged or repeated exposure.

Components:

Cefuroxime:

Assessment : May cause damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cefuroxime:

Species : Rat NOAEL : 900 mg/kg Application Route : Subcutaneous

Exposure time : 3 M

Symptoms : No adverse effects.

Species : Dog

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

NOAEL : 400 mg/kg LOAEL : 1,600 mg/kg

Application Route : Oral Exposure time : 27 W Target Organs : Blood

Symptoms : Gastrointestinal disturbance

Species : Monkey
NOAEL : 450 mg/kg
Application Route : Subcutaneous

Exposure time : 1 M

Target Organs : Blood, Urinary tract

Remarks : May cause damage to organs.

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Cefuroxime:

General Information : Repeated contact may cause allergic reactions in very sus-

ceptible persons.

Inhalation : Symptoms: Nausea, Vomiting, Abdominal pain, vaginitis,

Headache, Dizziness, dry mouth, Fatigue, constipation, colitis

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cefuroxime:

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Persistence and degradability

No data available

Bioaccumulative potential

Components:

Cefuroxime:

Partition coefficient: n-

octanol/water

: log Pow: -0.429

Mobility in soil

No data available

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste

handling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Respiratory or skin sensitization

Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with

known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

US State Regulations

Pennsylvania Right To Know

Glycerides, mixed C8-10 and succinyl 91744-56-8 Cefuroxime 55268-75-2

The ingredients of this product are reported in the following inventories:

AICS : not determined


DSL : not determined

IECSC : not determined

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



Special hazard

HMIS® IV:



HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organiza-

according to the OSHA Hazard Communication Standard



Cefuroxime Formulation

Version Revision Date: SDS Number: Date of last issue: 09/30/2023 2.3 11/30/2023 10844546-00005 Date of first issue: 09/06/2022

tion; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety

Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Revision Date : 11/30/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8